ATAI Competitors

We are Compass, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. We believe people living with mental health conditions deserve the possibility of a better future. Our initial focus is advancing COMP360, a proprietary, investigational synthetic psilocybin treatment being evaluated for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Our goal is to advance treatments that move the field of psychiatry towards treatment options that offer rapid onset and sustained durability, with infrequent dosing. We’re driven by our purpose of unlocking pathways to be—opening futures filled with possibility. Together, we’re on an ambitious journey toward enabling people living with mental health conditions to find clarity through self-discovery. Every journey needs a Compass.

Built from a decade of voice and emotion research. To build emotionally intelligent voice AI, we first had to define what “good” sounds like – not just acoustically, but perceptually and in real human conversations. That led us to build the research infrastructure behind expressive, trustworthy voice AI: scientifically grounded datasets, speech models, evaluation frameworks, and human preference pipelines. Today, we make that infrastructure available to frontier labs and AI-native companies building the next generation of voice. Whether you’re building foundation models, fine-tuning voice agents, or evaluating production systems, Hume provides the tools to measure, improve, and align voice AI the way people actually experience them.

MindMed is now Definium Therapeutics, a rebrand that reflects our commitment to forging a new era of psychiatry by applying precision to psychedelic medicine. Follow our new page at the link below!